This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.
5 Stocks Near 52-Week High: Is More Upside in the Cards?
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels with potential to scale higher.
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.
5 Low-Beta Stocks to Buy as Trade Conflict Intensifies
by Swarup Gupta
Since trade tensions could drastically dent investor confidence, picking value stocks with low-beta looks like a smart option at this point.
Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.
Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
by Zacks Equity Research
Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
5 Stocks Near 52-Week High With More Room to Run
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels and still with plenty of room for upside.
5 Best Bargain PEG Stocks That Value Investors Love
by Zacks Equity Research
While P/E alone fails to identify a true value stock, PEG helps to find the intrinsic value of a stock.
Jazz Pharmaceuticals (JAZZ) Up 16.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q1 and also raises the lower end of its earnings and sales guidance for 2018.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?
by Zacks Equity Research
Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.
Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?
by Zacks Equity Research
In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.
Concert Pharmaceuticals Plunges on Patent Petition Setback
by Zacks Equity Research
Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.
ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632
by Zacks Equity Research
ImmunoGen (IMGN) begins a phase I study to evaluate its anti-CD123 antibody-drug conjugates, IMGN632, for treating patients with hematological malignancies.
Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder
by Zacks Equity Research
Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.
ImmunoGen to Push Leukemia Candidate into Phase I Trial
by Zacks Equity Research
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%
by Zacks Equity Research
Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.
Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher
by Zacks Equity Research
Synergy Pharmaceuticals (SGYP) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
by Zacks Equity Research
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the Day